-- Scott Roberts
FRIDAY, Aug. 19 (HealthDay News) -- A new treatment called
Adcetris (brentuximab vedotin) has been approved by the U.S. Food
and Drug Administration to treat Hodgkin's lymphoma (HL) and a rare
type of lymphatic-system cancer called systemic anaplastic large
cell lymphoma (ALCL).
The antibody-drug combination directs an antibody at a type of
lymphoma cell called CD30, the agency said in a news release.
Adcetris is the first treatment to combat Hodgkin's lymphoma
approved by the FDA since 1977, and the first one designed to treat
ALCL, the agency said.
In clinical testing, the most common reported side effects of
Adcetris were a decrease in white blood cells, nerve damage,
fatigue, nausea, anemia, upper respiratory infection, diarrhea,
fever, cough, vomiting and low levels of blood platelets.
The agency release also advised pregnant women that the
treatment could harm a fetus, but did not say how.
The treatment is marketed by Washington state-based Seattle
The FDA has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.